Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
May 26, 2023
CRSP Sees Phenomenal Growth with Tickeron's AI Trading Robot, Garnering 4.57% Profit

CRSP Sees Phenomenal Growth with Tickeron's AI Trading Robot, Garnering 4.57% Profit

This article discusses the performance of an AI trading robot, specifically the Trend Trader: Popular Stocks (TA&FA) robot from Tickeron's robot factory. We will analyze its recent success in generating a 4.57% return for CRSP (Crispr Therapeutics AG) over a week. Furthermore, we will delve into technical indicators such as the Moving Average Convergence Divergence (MACD) and examine the earnings results to provide a comprehensive analysis of CRSP's performance.

AI Trading Robot's Performance: The Trend Trader: Popular Stocks (TA&FA) AI trading robot has demonstrated impressive performance within Tickeron's robot factory. During the specified week, it generated a substantial return of 4.57% for CRSP. This achievement indicates the potential effectiveness of utilizing AI algorithms to identify trading opportunities and make informed investment decisions.

Technical Analysis: MACD Indicator: One key technical indicator used to evaluate stock trends is the Moving Average Convergence Divergence (MACD). For CRSP, the MACD turned positive on May 4, 2023. Examining historical instances when CRSP's MACD turned positive, we find that the stock continued to rise in 40 out of 48 cases over the following month. This data suggests that there is an 83% chance of a continued upward trend for CRSP.

Earnings Results: The latest earnings report for CRSP, released on May 8, revealed earnings per share (EPS) of -67 cents. Notably, this figure exceeded the estimate of -174 cents, indicating a positive surprise. With 571.40K shares outstanding, the current market capitalization of CRSP stands at 5.19 billion dollars.

Conclusion: The performance of the Trend Trader: Popular Stocks (TA&FA) AI trading robot from Tickeron's robot factory highlights the potential of AI algorithms in the realm of stock trading. Its ability to generate a notable return of 4.57% for CRSP over a week demonstrates the effectiveness of using AI for identifying profitable opportunities.

Additionally, the positive turn of the MACD indicator for CRSP further supports the notion of a continued upward trend. Historical data indicates that in the majority of cases where CRSP's MACD turned positive, the stock price rose over the following month, suggesting an 83% chance of a continued upward movement.

Furthermore, the recent earnings report for CRSP exceeded expectations, with an EPS of -67 cents beating the estimated -174 cents. These positive results contribute to a favorable outlook for the company.

It is important to note that while technical analysis and AI trading algorithms provide valuable insights, they should be used in conjunction with other fundamental and market analysis tools.

Related Ticker: CRSP

Momentum Indicator for CRSP turns positive, indicating new upward trend

CRSP saw its Momentum Indicator move above the 0 level on June 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for CRSP just turned positive on June 17, 2026. Looking at past instances where CRSP's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

CRSP moved above its 50-day moving average on June 17, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CRSP crossed bullishly above the 50-day moving average on June 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CRSP advanced for three days, in of 257 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CRSP moved out of overbought territory on July 07, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRSP declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRSP broke above its upper Bollinger Band on July 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRSP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.213) is normal, around the industry mean (22.980). P/E Ratio (0.000) is within average values for comparable stocks, (38.292). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.534). CRSP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). CRSP's P/S Ratio (5000.000) is very high in comparison to the industry average of (407.380).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRSP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 126.5B. VRTX holds the highest valuation in this group at 126.5B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 3%. For the same Industry, the average monthly price growth was 14%, and the average quarterly price growth was 1,750%. CRNX experienced the highest price growth at 116%, while CRIS experienced the biggest fall at -97%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -1%. For the same stocks of the Industry, the average monthly volume growth was -26% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 80
Price Growth Rating: 52
SMR Rating: 94
Profit Risk Rating: 92
Seasonality Score: 2 (-100 ... +100)
View a ticker or compare two or three
CRSP
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of gene-based medicines

Industry Biotechnology

Profile
Details
Industry
Biotechnology
Address
Baarerstrasse 14
Phone
+41 415613277
Employees
393
Web
https://www.crisprtx.com
Interact to see
Advertisement
Aon plc (AON) reported third-quarter 2025 revenue of $3.997 billion, representing a 7% year-over-year increase with equal organic growth. Adjusted earnings per share came in at $3.05, exceeding expectations. In late November, Moody’s reaffirmed Aon’s Baa2 credit rating and revised the outlook to positive, citing reduced leverage following the NFP acquisition.
Air Products and Chemicals, Inc. (APD) entered the spotlight after announcing advanced discussions with Yara International on December 8 to collaborate on low-emission ammonia projects. While the strategic direction aligns with global decarbonization trends, uncertainty around execution and capital requirements triggered a 9.45% one-day decline in the stock.
Lockheed Martin and RTX Corporation are two of the most prominent names in the aerospace and defense industry, both positioned to benefit from heightened global security concerns and sustained U.S. military spending.
As 2025 winds down, the Savings Banks sector reflects a mix of stability, innovation, and AI-driven disruption. Among the most closely watched tickers—SOFI Technologies (SOFI), Ally Financial (ALLY), and PayPal Holdings (PYPL)—investors have witnessed contrasting stories of growth, valuation, and market perception.
Ondas Holdings (ONDS) is a wireless technology company focused on delivering secure, long-range communications for industrial Internet of Things (IoT) and data networking applications. Its solutions are built to support mission-critical operations across sectors such as rail, energy, maritime, infrastructure, and industrial automation.
Ciena’s growth is driven by expanding offerings in optical networking, network automation software, and 5G transport infrastructure, complemented by services designed to help customers modernize and future-proof their networks. Its evolving technology portfolio addresses the rising complexity, speed, and reliability requirements of today’s communications environment.
Marathon Digital Holdings (MARA) and Riot Platforms (RIOT) are two leading companies in the Bitcoin mining industry, each operating energy-intensive infrastructure to capitalize on cryptocurrency market cycles. This comparison is especially relevant amid ongoing Bitcoin price volatility and growing interest in digital assets and AI-related infrastructure.
Roivant Sciences has delivered strong year-to-date performance, with shares up roughly 82%, driven by encouraging pipeline developments and increased investment in high-potential subsidiaries such as Immunovant.
MP Materials Corp. (MP) and USA Rare Earth, Inc. (USAR) are central to the United States’ push to establish a secure, domestic supply of rare earth elements—materials critical to electric vehicles, renewable energy, and defense technologies. As geopolitical tensions and supply chain vulnerabilities intensify, these two companies offer distinct approaches to addressing U.S. dependence on foreign sources.
The Invesco QQQ Trust (NASDAQ: QQQ) remains one of the most closely followed ETFs worldwide, offering investors direct exposure to the NASDAQ-100 Index®. In the most recent data, QQQ has gained a notable +20.16% year-to-date, even as markets experienced bouts of elevated volatility.
Pioneer Power's 2025 highlights include the expansion of its mobile power and charging footprint with new orders and partnerships; the launch of a new suite of e-Boost solutions for off-grid EV charging; the rebranding of HomeBoost as PowerCore with events in December; the introduction of PRYMUS in December; and a new five-year contract for network transformers with a regional utility provider.
An AI-driven comparison between Palantir (PLTR) and Oracle (ORCL) points to Palantir as the more compelling investment heading into 2026. The analysis highlights PLTR’s AI-native platforms, which enable real-time, data-driven decision-making across fast-growing sectors such as government, defense, and enterprise analytics.
An AI-driven comparison between D-Wave Quantum (QBTS) and IonQ (IONQ) points to IonQ as the stronger opportunity heading into 2026. The analysis highlights IONQ’s gate-based, trapped-ion quantum architecture, which supports a wide range of algorithms and positions the company for broader adoption across AI, simulation, and cryptography.
An AI-driven comparison of Rigetti Computing (RGTI) and D-Wave Quantum (QBTS) points to Rigetti as the more compelling opportunity heading into 2026. The analysis highlights RGTI’s gate-based quantum architecture, which supports universal quantum computing and a wide range of complex algorithms. While D-Wave remains a leader in quantum annealing for optimization problems, Rigetti’s full-stack, gate-based approach offers greater scalability and broader long-term applications.
An AI-driven comparison of Rigetti Computing (RGTI) and TeraWulf (WULF) points to TeraWulf as the more attractive investment heading into 2026. The analysis emphasizes WULF’s large-scale digital infrastructure supporting Bitcoin mining and high-performance computing (HPC), which generates immediate revenue in expanding digital asset and AI-driven markets.
An AI-driven comparison between Rocket Lab USA (RKLB) and Planet Labs (PL) identifies Rocket Lab as the more compelling investment heading into 2026. The analysis highlights RKLB’s vertically integrated space services and consistent launch performance, which position the company to benefit from rising demand for satellite deployment and space infrastructure.
An AI-driven comparison of Tempus AI (TEM) and Doximity (DOCS) points to Tempus AI as the more compelling investment opportunity heading into 2026. The analysis highlights TEM’s AI-powered precision medicine platform, which applies advanced analytics and genomic data to transform diagnostics and treatment in oncology and cardiology.
An AI-driven comparison of UnitedHealth Group (UNH) and CVS Health (CVS) points to UnitedHealth as the stronger investment heading into 2026. The analysis emphasizes UNH’s deeply integrated healthcare model, combining insurance, data analytics, pharmacy services, and care delivery into a single ecosystem. This structure provides resilience and earnings stability in an increasingly complex healthcare environment.
An AI-driven comparison of Netflix (NFLX) and Disney (DIS) points to Netflix as the more attractive investment heading into 2026. The analysis emphasizes Netflix’s focused, pure-play streaming model and its continued investment in original content, which support strong subscriber engagement as viewing habits shift further toward digital platforms.